Experienced in Interstitial Nephritis

Julie Ho

MB, CA 
Experienced in Interstitial Nephritis
MB, CA 
OverviewLocationsClinical Research

Overview

Julie Ho practices in Canada. Ms. Ho is rated as an Experienced expert by MediFind in the treatment of Interstitial Nephritis. Her top areas of expertise are Vulvar Cancer, Interstitial Nephritis, Acute Tubular Necrosis, Kidney Transplant, and Tissue Biopsy.

Her clinical research consists of co-authoring 103 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Interstitial Nephritis.

Gender
Female

Locations

MB, Canada
Other Locations
Winnipeg, MB, Canada
Montreal, QC, Canada
Vancouver, BC, Canada
North Vancouver, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Controlled Trial of Urine CXCL10 Chemokine Monitoring Post-renal Transplant
A Randomized Controlled Trial of Urine CXCL10 Chemokine Monitoring Post-renal Transplant
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2025
Intervention Type: Procedure
Study Phase: Phase 2/Phase 3
Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)
Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug, Biological
Study Drugs: Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Prednisone, Diphenhydramine
Study Phase: Phase 2
View 1 Less Clinical Trial

103 Total Publications

Corrigendum to "HLA-DQ heterodimer mismatch as a predictor of post-transplant alloimmunity and allograft survival". [Hum. Immunol. 86 (2025) 111345].
Corrigendum to "HLA-DQ heterodimer mismatch as a predictor of post-transplant alloimmunity and allograft survival". [Hum. Immunol. 86 (2025) 111345].
Journal: Human immunology
Published: July 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ho's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile